Gilead Sciences on Thursday reported flat second-quarter earnings on slightly higher revenue and raised its full-year ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 1 ...

Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio and ...

Amid the questions about the Yeztugo rollout, Gilead’s second quarter performance offered some reassurance about the ...

Gilead Sciences, Inc. (NASDAQ:GILD) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Gilead Sciences, Inc. (NASDAQ:GILD) has received a favorable opinion from the European Medicines ...

Gilead Sciences, Inc.'s HIV dominance with Biktarvy & Yeztugo boosts revenue potential. Click for more about GILD and its ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...

The U.S. Preventive Services Task Force makes recommendations for preventive services—including Gilead’s twice-yearly HIV ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Gilead stock briefly broke out Friday after the biotech company beat second-quarter forecasts amid its newest launch in HIV ...

Discover key insights from Gilead Sciences' Q2 2025 earnings call, featuring Yeztugo's groundbreaking launch, upward guidance revisions, and strong ...